News

Article

Rentschler Fill Solutions Announces Agreement for US-Market Drug

Rentschler Fill Solutions and Ultragenyx announce fill and finish agreement for the US commercial supply of Mepsevii.

Rentschler Fill Solutions GmbH announced on May 30, 2018 a collaboration with Ultragenyx Pharmaceutical, Inc. for the fill/finish production of the injectable Mepsevii (vestronidase alfa), a recombinant form of the human enzyme beta-glucuronidase, to treat patients with mucopolysaccharidosis (MPS) VII, a rare genetic disorder.

Mepsevii, developed by Ultragenyx in collaboration with Rentschler Biopharma SE in Laupheim, Germany, was approved by the US FDA in November 2017. An application for marketing approval in Europe is under review.

The drug product will be transferred from Rentschler Biopharma SE to Austria-based Rentschler Fill Solutions for fill/finish activities. Rentschler Biopharma will continue to manufacture the drug substance.

Rentschler Fill Solutions offers services for the aseptic filling and freeze drying of drug products.

Source: Rentschler Fill Solutions

 

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content